<DOC>
	<DOCNO>NCT00168090</DOCNO>
	<brief_summary>The purpose study test safety effectiveness Humate-P® prevent bleeding patient von Willebrand Disease undergo surgery .</brief_summary>
	<brief_title>Study Safety Efficacy Antihemophilic Factor/Von Willebrand Factor Complex Surgical Subjects With Von Willebrand Disease ( vWD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Blood Platelet Disorders</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Key Subjects age Clinical laboratory diagnosis vWD expect show hemostatic response DDAVP Require substitution vWF/FVIII complex due surgery Key Known significant hemostatic disorder vWD Acquired vWD Known antibody FVIII vWF Known platelet type vWD Emergency surgery surgery degree urgency permit completion pharmacokinetic assessment require study protocol History allergic reaction HumateP® Treatment investigational drug last four week entry study ( exception trial concern antiHIV agent ) Progressive fatal disease/life expectancy le 6 month Treatment DDAVP , cryoprecipitate , whole blood , plasma plasma derivative contain substantial quantity FVIII and/or vWF within 5 day presurgical pharmacokinetic assessment Pediatric patient insufficient body weight permit PK sample Woman first 20 week pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>von Willebrand Factor</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Factor VIII</keyword>
</DOC>